Join us for an exclusive in-person Fireside Founder Chat with Dr. Nan Fang, the founder of Singleron, a pioneer in single-cell sequencing technologies. In this intimate Fireside chat, you'll learn firsthand how she built and scaled Singleron from a fledgling startup to a company with over 400 employees. You will get to hear about her career journey from an MNC to a growing startup, and how she navigated the bioentrepreneurship ecosystems in both Asia and Europe.

Speaker's Profile:

Dr. Fang has more than 15 years’ industry experience in leading international biotech companies with product development and leadership experience in Europe, US, and China. Prior to founding Singleron, she was Associate Director and Head of Product Development for the Universal NGS Market Program at QIAGEN, Germany.

Dr. Fang has led the rapid growth of Singleron after its incorporation in 2018, turning the company into a major player in the field of single cell analysis. With more than 400 employees in China, Europe, and the US, the company is now serving more than 500 customer organizations and pioneering the translation of cutting-edge single cell technologies to clinics and drug development.

Dr. Fang has won numerous awards and honors, including Jiangsu Province Entrepreneur of the Year 2019; Forbes China Top 50 Women in Tech 2020; Forbes China Up-and-Coming Business Women 2021; Harvard Business Review Ram Charan Management Practice Award 2021; and Fortune China Top 50 MPWs of Future 2021.

About Singleron:

Founded in 2018, Singleron develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in China, Germany, Singapore and the US. Its products are used in over 500 hospitals, research institutes, and pharmaceutical companies worldwide, including top pharmaceutical companies such as AstraZeneca and AbbVie.

Singleron has recently acquired Proteona Pte Ltd, a Singapore based precision medicine company spun out from A*STAR and NUS. Together they will offer single-cell products, services and data analytics to the local community.